Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Compounded semaglutide is a version of the drug mixed by a compounding pharmacy rather than manufactured by Novo Nordisk. It became widespread during the global Ozempic shortage of 2023 and 2024, when demand vastly outstripped branded supply and patients and physicians turned to compounding pharmacies that produced their own semaglutide formulations.
The FDA explicitly warned against compounded semaglutide in 2024, citing safety concerns and documented cases of patients receiving incorrect doses due to labelling confusion between milligrams and units. Understanding what compounded semaglutide is — and what the risks are — matters for anyone considering it.
How Compounding Works
Pharmaceutical compounding is the preparation of customised medications for individual patients. It is legitimate and important for patients who need special doses, formulations, or combinations not available commercially. Compounding pharmacies are regulated by state pharmacy boards in the US and equivalent bodies in other countries.
During drug shortages, regulations in some countries allow compounding pharmacies to produce copies of the shortage drug. This created a large market for compounded semaglutide when Ozempic and Wegovy supplies were constrained.
Compounded semaglutide is typically produced from semaglutide base — a raw pharmaceutical ingredient — rather than from the branded manufactured product. The pharmacy then formulates it into injections, often at lower cost than the branded version.
Why the FDA Issued Warnings
The FDA issued specific safety communications about compounded semaglutide for several reasons:
Dosing errors: Semaglutide concentration in compounded products varies. Patients accustomed to the branded pen's pre-set dose faced significant risk when using vials that required manual measurement. Errors in drawing the correct volume from a vial led to overdoses with severe adverse events.
Unapproved additives: Some compounded semaglutide products contained additional ingredients — including semaglutide sodium salt or other modifications — not present in the approved drug and not studied for safety.
Quality control: Compounding pharmacies do not undergo the same manufacturing quality controls as pharmaceutical manufacturers. Sterility, potency, and purity are not guaranteed at the same standard.
Authenticity: The market for compounded semaglutide created conditions where counterfeit or substandard products could enter the supply chain, particularly through online pharmacies.
The Risk Is Real, Not Theoretical
The FDA's adverse event database received hundreds of reports associated with compounded semaglutide, including nausea and vomiting severe enough to require hospitalisation, hypoglycaemia from dosing errors, and cases of serotonin syndrome from unapproved additives. Several hospitalisations were attributed directly to 10-fold dosing errors from concentration confusion.
The Safer Alternative for Pakistani Patients
For Pakistani patients considering compounded semaglutide, the most important question is whether there is a DRAP-registered alternative that targets the same GLP-1 pathway. There is. METASLIM is a physician-formulated GLP-1 sublingual supplement registered with DRAP and produced under MD-reviewed protocols. It is not pharmaceutical semaglutide, but it provides GLP-1 pathway support without the authenticity risks, cold chain failures, and regulatory grey area of compounded imports.